Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | STI-1492 |
Trade Name | |
Synonyms | STI 1492|STI1492 |
Drug Descriptions |
STI-1492 are allogeneic T-cells engineered to knockout TCR alpha and express a dimeric antigen receptor targeting CD38 and containing 4-1BB and CD3-zeta signaling domains, which potentially induce toxicity against tumor cells expressing CD38 (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C182613 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
STI-1492 | STI-1492 | 0 | 1 |